{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-292706","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.277459+00:00","generated_at":"2026-06-07T14:58:07.493470+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio raises $14.4M in private placement; potential total up to $46.9M via warrant exercises","bullets":["Initial gross proceeds of $14.4M from selling 11.8M units at $1.22/unit; extends cash runway into 2025.","Investors get Series A warrants ($1.25 strike) exercisable upon INB-100 11-month data announcement for up to $14.8M additional.","Series B warrants ($1.50 strike) redeemable upon 22-month data; potential $17.7M extra if all exercised.","Pre-funded warrants at $0.0001 exercise price included; Cantor Fitzgerald acted as sole placement agent.","Proceeds to fund clinical development of gamma-delta T cell therapies and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-292706","json":"https://secwatch.observer/filing/0001193125-23-292706.json","markdown":"https://secwatch.observer/filing/0001193125-23-292706.md","text":"https://secwatch.observer/filing/0001193125-23-292706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/d634758d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:58:07.493470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93456af317cb1245a1acc8ad691487545bf3d3c2","claim":"IN8BIO, INC. entered into Securities Purchase Agreement with the purchasers named therein (the Investors) valued at $14.4 million (effective 2023-12-11).","evidence_excerpt":"On December 11, 2023, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 11,823,829 units (the “Units”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein (the Investors)"},{"label":"Value","value":"$14.4 million"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"},{"claim_id":"b162bc4b1428183a7703179558904ec698ad9a02","claim":"IN8BIO, INC. entered into Registration Rights Agreement with the Investors (effective 2023-12-11).","evidence_excerpt":"Also on December 11, 2023, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Company agreed to register for resale the Shares and the Common Stock underlying the Warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Investors"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}